about
MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathwayRole of T198 modification in the regulation of p27(Kip1) protein stability and functionp27(Kip1)-stathmin interaction influences sarcoma cell migration and invasionLoss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells.p27(kip1) functional regulation in human cancer: a potential target for therapeutic designs.Linking inflammation to cell cycle progression.Genetic characterization of p27(kip1) and stathmin in controlling cell proliferation in vivo.p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability.Stathmin activity influences sarcoma cell shape, motility, and metastatic potential.Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway.p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms.CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.SUMOylation regulates p27Kip1 stability and localization in response to TGFβ.Characteristic in vitro evolution pattern of foot and mouth disease virus A81/Castellanos/Arg/87.A new epitope presenting system displays a HIV-1 V3 loop sequence and induces neutralizing antibodies.Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro.Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ.Modification of foot-and-mouth disease virus after serial passages in the presence of antiviral polyclonal sera.p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis.Inhibition of breast cancer local relapse by targeting p70S6 kinase activity.Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFR Tyrosine Kinase Inhibitor.Immunoreactivity of chimeric proteins carrying the HIV-1 epitope IGPGRAF. Correlation between predicted conformation and antigenicity.V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system.Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case reportAge-Related Persistent Clonal Expansions of CD28−Cells: Phenotypic and Molecular TCR Analysis Reveals both CD4+and CD4+CD8+Cells with Identical CDR3 SequencesUSP1 links platinum resistance to cancer cell dissemination by regulating Snail stabilityDownregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast CancerIdentification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer CellsSplicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activityStathmin Is Required for Normal Mouse Mammary Gland Development and Δ16HER2-Driven Tumorigenesis
P50
Q24294441-3DEFEB24-FA26-43C7-90EB-555AFDCBE8A2Q27349944-A9536BE7-4722-4F66-A7C7-A7A1EEDA34A9Q28587847-38410C81-61D7-4317-A66E-FEA520EBF0E8Q33677415-28C028C7-B413-4F57-9905-1FEA2AB42FE6Q34434324-498A5CA2-7B5E-4394-A616-531554D6B13DQ35768612-51795D8D-9CED-44EB-9389-CED04DC8409DQ36182287-CEF20387-271D-4091-82F5-0058AF1EA5E6Q36300446-1001E2CC-8AE5-467E-8E9F-7904437F3E8DQ36631230-A092E867-79FC-449E-8728-57D9379E395BQ36870100-AF57456E-AFCE-4B31-9C90-286CCE04BA00Q37266266-A76EADFE-E763-48AE-A9B1-6A8B9C520CC5Q37662085-7BF43531-4AD7-4FB6-B952-F89C2860F1AAQ38639827-D58B8F71-B3F9-4A3D-803D-E417929062C7Q38695855-47B115E3-534F-49D0-974D-2A2432FE3D03Q38829266-0159759E-F063-4135-917F-C57B350AA38EQ41112989-2C55AC09-EC6A-4B60-B706-6411937F761FQ41299147-39A8E3A7-226C-4F47-A982-9D62A94E68D5Q44131351-2E801644-AD8D-455C-A81B-4CFFC35225BFQ44503051-068C4EF6-243F-4742-993B-351239310745Q45845509-4A45932F-7F6B-4962-9C9E-231361B154CEQ45877613-655E9A21-1538-4F2D-92CA-9FB7E1878439Q47900139-18322491-5E05-48B8-92BC-5425CC9A7D24Q50091449-4D1715B3-20EC-431A-B5C8-CE4BAC118570Q52536301-EA29CA30-5147-4E39-860C-4727333BBE54Q52552211-701A8614-37CD-4702-88A9-827444E08F46Q60045782-344577B0-279D-4B48-AEB9-CFCB84D7AF5AQ61314283-D97DCFF0-B1BA-43BC-99C3-C8EEA1FBB1BBQ64062880-780933C8-3DF4-41D6-A97B-A918B15A0C19Q92162066-42552D40-6BCC-4224-9FA2-4F56F9A2EFDAQ92255745-DA79734E-DB75-4CD9-AECE-A8ABB8FCC3F4Q93217180-8ECD3934-633C-4771-BB11-0C51D7416337Q93381025-C3402013-D110-48ED-9352-2D6E71DD43AA
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Monica Schiappacassi
@ast
Monica Schiappacassi
@en
Monica Schiappacassi
@es
Monica Schiappacassi
@nl
Monica Schiappacassi
@sl
type
label
Monica Schiappacassi
@ast
Monica Schiappacassi
@en
Monica Schiappacassi
@es
Monica Schiappacassi
@nl
Monica Schiappacassi
@sl
prefLabel
Monica Schiappacassi
@ast
Monica Schiappacassi
@en
Monica Schiappacassi
@es
Monica Schiappacassi
@nl
Monica Schiappacassi
@sl
P106
P1153
6602582130
P21
P31
P496
0000-0003-4804-4291